NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels [clinicaltrials:NCT00279084]

Bio2RDF uri

NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels [clinicaltrials:NCT00279084]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00279084

Bio2RDF identifier

NCT00279084

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00279084

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00279084

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:0328003ddb605605211a25663c42d817

brief summary [clinicaltrials_vocabulary:brief-summary]

In type 2 diabetics, pr ...... clearance of 25 - 60 ml/min.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

NEPHRODIAB2 Prospective Random ...... fect of Two Haemoglobin Levels

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:f53d410d94ab21d761332b73159491f1]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:099fbb4990e69cfd00a9a2e70664f427]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:0ff404478fe0cf4a46cbccb344f7336a]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:107239e52195e4699fadefb4900efe20]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:406b4e332b89563dd04740f4558d1040]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:4b9bf6edde5e65bcf0c8b8082193faf5]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:4c4a8cf232dda4b4f625dbee724c750f]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:527d546aac1bc56a0ebd2bfe5fedb30d]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:6f1e36b73631208fc40e808d69257c6f]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:bad2b0eebaa3ebcbc678cba1a1eaaa5f]

Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period. [clinicaltrials_resource:dd1085cf510abe0aeb5b93a3e278d4ce]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00279084 [clinicaltrials_resource:68c31744c72af571a60e957e8b2b83f4]

enrollment [clinicaltrials_vocabulary:enrollment]

204

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L [clinicaltrials_resource:06fc5384e1108822fe2c8257b578f757]

GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L. [clinicaltrials_resource:2703ce20e96811603c2021c2e770d81b]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Epoetin alfa [clinicaltrials_resource:3f972528b05cedf4d57b0b1603c54e11]

keyword [clinicaltrials_vocabulary:keyword]

Anaemia

http://www.w3.org/2001/XMLSchema#string

Chronic kidney disease

http://www.w3.org/2001/XMLSchema#string

Randomized trial

http://www.w3.org/2001/XMLSchema#string

Type 2 diabetes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2007-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Hospices Civils de Lyon [clinicaltrials_resource:f055c595c46d1bd661fe303284918878]

location [clinicaltrials_vocabulary:location]

Joëlle Gillet [clinicaltrials_resource:b52e02a69a884d7af35678efec87624a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00279084

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Prospective Randomized Control ...... nd With Chronic Kidney Disease

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2.00331494140625e+3

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

Emmanuel VILLAR, MD [clinicaltrials_resource:fbd6d862042392076e5b55507cc9da02]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

France: Ministry of Health [clinicaltrials_resource:87d373f2dff53c89ea4ef93b626b2e14]

source [clinicaltrials_vocabulary:source]

Hospices Civils de Lyon [clinicaltrials_resource:f055c595c46d1bd661fe303284918878]

start date [clinicaltrials_vocabulary:start-date]

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00279084 study design [clinicaltrials_resource:2f8691639c632972c8fa816f1dbae48c]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00279084

verification date [clinicaltrials_vocabulary:verification-date]

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00279084

http://www.w3.org/2001/XMLSchema#string

title

NEPHRODIAB2 Prospective Random ...... fect of Two Haemoglobin Levels

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

NEPHRODIAB2 Prospective Random ...... s [clinicaltrials:NCT00279084]

@en